KRAS and non-small cell lung carcinoma: The disparate nature of in vitro and in vivo metabolism is exemplified by a recent study that took advantage of two transgenic mouse models of KRAS-driven non-small cell lung cancer (NSCLC; Davidson et al., 2016).